DS-7011a

DRUG2 trials

Sponsors

Daiichi Sankyo

Conditions

Systemic Lupus Erythematosus

Phase 1

A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects

CompletedNCT05203692

Daiichi SankyoSystemic Lupus Erythematosus

Start: 2022-02-02End: 2023-03-22Updated: 2023-04-11

A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

CompletedNCT05638802

Daiichi SankyoSystemic Lupus Erythematosus

Start: 2023-06-07End: 2025-04-01Updated: 2026-05-28

Related Papers

First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of DS‐7011a, an Anti‐TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

The Journal of Clinical Pharmacology2024-08-226 citations